Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 49

1.

Neoadjuvant hormonal therapy for low-risk prostate cancer induces biochemical recurrence after radical prostatectomy via increased lymphangiogenesis-related parameters.

Miyata Y, Nakamura Y, Yasuda T, Matsuo T, Ohba K, Furusato B, Fukuoka J, Sakai H.

Prostate. 2017 Oct;77(14):1408-1415. doi: 10.1002/pros.23402. Epub 2017 Aug 28.

2.

Ciliated muconodular papillary tumors of the lung with KRAS/BRAF/AKT1 mutation.

Udo E, Furusato B, Sakai K, Prentice LM, Tanaka T, Kitamura Y, Tsuchiya T, Yamasaki N, Nagayasu T, Nishio K, Fukuoka J.

Diagn Pathol. 2017 Aug 22;12(1):62. doi: 10.1186/s13000-017-0651-2.

3.

Clinicopathological importance of anterior prostate cancer in Japanese Men.

Sato S, Takahashi H, Kimura T, Egawa S, Furusato B, Ikegami M.

Pathol Int. 2017 Mar;67(3):156-162. doi: 10.1111/pin.12513. Epub 2017 Feb 1.

PMID:
28145029
4.

Green Tea Polyphenol Induces Changes in Cancer-Related Factors in an Animal Model of Bladder Cancer.

Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J, Sakai H.

PLoS One. 2017 Jan 31;12(1):e0171091. doi: 10.1371/journal.pone.0171091. eCollection 2017.

5.

Time Trends in Histological Features of Latent Prostate Cancer in Japan.

Kimura T, Takahashi H, Okayasu M, Kido M, Inaba H, Kuruma H, Yamamoto T, Furusato B, Furusato M, Wada T, Egawa S.

J Urol. 2016 May;195(5):1415-20. doi: 10.1016/j.juro.2015.11.068. Epub 2015 Dec 8.

PMID:
26678955
6.

Increased aPKC Expression Correlates with Prostatic Adenocarcinoma Gleason Score and Tumor Stage in the Japanese Population.

Perry AS, Furusato B, Nagle RB, Ghosh S.

Prostate Cancer. 2014;2014:481697. doi: 10.1155/2014/481697. Epub 2014 Apr 29.

7.

Differences in prostate cancer grade, stage, and location in radical prostatectomy specimens from United States and Japan.

Takahashi H, Epstein JI, Wakui S, Yamamoto T, Furusato B, Zhang M.

Prostate. 2014 Feb;74(3):321-5. doi: 10.1002/pros.22754.

PMID:
24259155
8.

Evaluation of ERG responsive proteome in prostate cancer.

Tan SH, Furusato B, Fang X, He F, Mohamed AA, Griner NB, Sood K, Saxena S, Katta S, Young D, Chen Y, Sreenath T, Petrovics G, Dobi A, McLeod DG, Sesterhenn IA, Saxena S, Srivastava S.

Prostate. 2014 Jan;74(1):70-89. doi: 10.1002/pros.22731. Epub 2013 Sep 21.

9.

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.

Leinonen KA, Saramäki OR, Furusato B, Kimura T, Takahashi H, Egawa S, Suzuki H, Keiger K, Ho Hahm S, Isaacs WB, Tolonen TT, Stenman UH, Tammela TL, Nykter M, Bova GS, Visakorpi T.

Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2333-44. doi: 10.1158/1055-9965.EPI-13-0333-T. Epub 2013 Oct 1.

10.

Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients.

Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, Kamata Y, van Leenders GJ, Visakorpi T, Egawa S.

Pathol Int. 2012 Nov;62(11):742-8. doi: 10.1111/pin.12006.

PMID:
23121605
11.

Elevated osteonectin/SPARC expression in primary prostate cancer predicts metastatic progression.

Derosa CA, Furusato B, Shaheduzzaman S, Srikantan V, Wang Z, Chen Y, Seifert M, Ravindranath L, Young D, Nau M, Dobi A, Werner T, McLeod DG, Vahey MT, Sesterhenn IA, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2012 Jun;15(2):150-6. doi: 10.1038/pcan.2011.61. Epub 2011 Nov 29. Erratum in: Prostate Cancer Prostatic Dis. 2012 Jun;15(2):210. Siefert, M [corrected to Seifert, M].

PMID:
22343836
12.

Novel human prostate epithelial cell culture models for the study of carcinogenesis and of normal stem cells and cancer stem cells.

Rhim JS, Li H, Furusato B.

Adv Exp Med Biol. 2011;720:71-80. doi: 10.1007/978-1-4614-0254-1_6. Review.

PMID:
21901619
13.

Inflammatory cytokine and chemokine expression in sympathetic ophthalmia: a pilot study.

Furusato E, Shen D, Cao X, Furusato B, Nussenblatt RB, Rushing EJ, Chan CC.

Histol Histopathol. 2011 Sep;26(9):1145-51. doi: 10.14670/HH-26.1145.

14.

Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients.

Furusato B, van Leenders GJ, Trapman J, Kimura T, Egawa S, Takahashi H, Furusato M, Visakorpi T, Hano H.

Pathol Int. 2011 Jul;61(7):409-14. doi: 10.1111/j.1440-1827.2011.02675.x. Epub 2011 Jun 8.

PMID:
21707844
15.

Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice.

van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, Trapman J.

Mod Pathol. 2011 Aug;24(8):1128-38. doi: 10.1038/modpathol.2011.65. Epub 2011 Apr 15.

16.

Targeted disruption of Ing2 results in defective spermatogenesis and development of soft-tissue sarcomas.

Saito M, Kumamoto K, Robles AI, Horikawa I, Furusato B, Okamura S, Goto A, Yamashita T, Nagashima M, Lee TL, Baxendale VJ, Rennert OM, Takenoshita S, Yokota J, Sesterhenn IA, Trivers GE, Hussain SP, Harris CC.

PLoS One. 2010 Nov 19;5(11):e15541. doi: 10.1371/journal.pone.0015541.

17.

Orbital solitary fibrous tumor: encompassing terminology for hemangiopericytoma, giant cell angiofibroma, and fibrous histiocytoma of the orbit: reappraisal of 41 cases.

Furusato E, Valenzuela IA, Fanburg-Smith JC, Auerbach A, Furusato B, Cameron JD, Rushing EJ.

Hum Pathol. 2011 Jan;42(1):120-8. doi: 10.1016/j.humpath.2010.05.021. Epub 2010 Nov 5.

PMID:
21056898
18.

Assessment of circulating tumor cells (CTCs) in prostate cancer patients with low-volume tumors.

Ali A, Furusato B, Ts'o PO, Lum ZP, Elsamanoudi S, Mohamed A, Srivastava S, Moul JW, Brassell SA, Sesterhenn IA, McLeod DG.

Pathol Int. 2010 Oct;60(10):667-72. doi: 10.1111/j.1440-1827.2010.02584.x.

PMID:
20846264
19.

Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence.

Hawksworth D, Ravindranath L, Chen Y, Furusato B, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Dec;13(4):311-5. doi: 10.1038/pcan.2010.31. Epub 2010 Sep 7.

PMID:
20820186
20.

CXCR4 and cancer.

Furusato B, Mohamed A, Uhlén M, Rhim JS.

Pathol Int. 2010 Jul;60(7):497-505. doi: 10.1111/j.1440-1827.2010.02548.x. Review.

PMID:
20594270
21.

ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification.

Furusato B, Tan SH, Young D, Dobi A, Sun C, Mohamed AA, Thangapazham R, Chen Y, McMaster G, Sreenath T, Petrovics G, McLeod DG, Srivastava S, Sesterhenn IA.

Prostate Cancer Prostatic Dis. 2010 Sep;13(3):228-37. doi: 10.1038/pcan.2010.23. Epub 2010 Jun 29.

22.

Ocular perivascular epithelioid cell tumor: report of 2 cases with distinct clinical presentations.

Furusato E, Cameron JD, Newsom RW, Fujishiro T, Kojima T, Specht CS, Fetsch JF, Furusato B, Sesterhenn IA, Rushing EJ.

Hum Pathol. 2010 May;41(5):768-72. doi: 10.1016/j.humpath.2009.12.006. Epub 2010 Mar 17.

PMID:
20236689
23.

Evaluation of the ETS-related gene mRNA in urine for the detection of prostate cancer.

Rice KR, Chen Y, Ali A, Whitman EJ, Blase A, Ibrahim M, Elsamanoudi S, Brassell S, Furusato B, Stingle N, Sesterhenn IA, Petrovics G, Miick S, Rittenhouse H, Groskopf J, McLeod DG, Srivastava S.

Clin Cancer Res. 2010 Mar 1;16(5):1572-6. doi: 10.1158/1078-0432.CCR-09-2191. Epub 2010 Feb 16.

24.

Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

Whitman EJ, Pomerantz M, Chen Y, Chamberlin MM, Furusato B, Gao C, Ali A, Ravindranath L, Dobi A, Sesterhenn IA, McLeod DG, Srivastava S, Freedman M, Petrovics G.

Cancer Epidemiol Biomarkers Prev. 2010 Jan;19(1):1-8. doi: 10.1158/1055-9965.EPI-08-1111. Erratum in: Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):890. Sestrehenn, Isabell A [corrected to Sesterhenn, Isabell A].

25.

Osteoblast-specific factor 2 expression in prostate cancer-associated stroma: identification through microarray technology.

Furusato B, Tsunoda T, Shaheduzzaman S, Nau ME, Vahey M, Petrovics G, McLeod DG, Naito S, Shirasawa S, Srivastava S, Sesterhenn IA.

Urology. 2010 Apr;75(4):768-72. doi: 10.1016/j.urology.2009.10.026. Epub 2009 Dec 29.

PMID:
20035976
26.

Clinicopathological behavior of single focus prostate adenocarcinoma.

Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, Brassell SA.

J Urol. 2009 Dec;182(6):2689-94. doi: 10.1016/j.juro.2009.08.055.

PMID:
19836800
27.

WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.

Furusato E, Hidayat AA, Man YG, Auerbach A, Furusato B, Rushing EJ.

Arch Ophthalmol. 2009 Aug;127(8):964-9. doi: 10.1001/archophthalmol.2009.183.

PMID:
19667332
28.

Quantitative expression of TMPRSS2 transcript in prostate tumor cells reflects TMPRSS2-ERG fusion status.

Mwamukonda K, Chen Y, Ravindranath L, Furusato B, Hu Y, Sterbis J, Osborn D, Rosner I, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Prostate Cancer Prostatic Dis. 2010 Mar;13(1):47-51. doi: 10.1038/pcan.2009.28. Epub 2009 Jul 14.

29.

The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma.

Tsunoda T, Furusato B, Takashima Y, Ravulapalli S, Dobi A, Srivastava S, McLeod DG, Sesterhenn IA, Ornstein DK, Shirasawa S.

Prostate. 2009 Sep 15;69(13):1398-403. doi: 10.1002/pros.20988.

PMID:
19479898
30.

PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume.

Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG.

J Urol. 2008 Nov;180(5):1975-8; discussion 1978-9. doi: 10.1016/j.juro.2008.07.060. Epub 2008 Sep 17.

PMID:
18801539
31.

Delineation of TMPRSS2-ERG splice variants in prostate cancer.

Hu Y, Dobi A, Sreenath T, Cook C, Tadase AY, Ravindranath L, Cullen J, Furusato B, Chen Y, Thangapazham RL, Mohamed A, Sun C, Sesterhenn IA, McLeod DG, Petrovics G, Srivastava S.

Clin Cancer Res. 2008 Aug 1;14(15):4719-25. doi: 10.1158/1078-0432.CCR-08-0531.

32.

Do patients with low volume prostate cancer have prostate specific antigen recurrence following radical prostatectomy?

Furusato B, Rosner IL, Osborn D, Ali A, Srivastava S, Davis CJ, Sesterhenn IA, McLeod DG.

J Clin Pathol. 2008 Sep;61(9):1038-40. doi: 10.1136/jcp.2008.057794. Epub 2008 Jun 13.

33.

TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation.

Sun C, Dobi A, Mohamed A, Li H, Thangapazham RL, Furusato B, Shaheduzzaman S, Tan SH, Vaidyanathan G, Whitman E, Hawksworth DJ, Chen Y, Nau M, Patel V, Vahey M, Gutkind JS, Sreenath T, Petrovics G, Sesterhenn IA, McLeod DG, Srivastava S.

Oncogene. 2008 Sep 11;27(40):5348-53. doi: 10.1038/onc.2008.183. Epub 2008 Jun 9.

PMID:
18542058
34.

Use of step-section histopathology to evaluate 18F-fluorocholine PET sextant localization of prostate cancer.

Kwee SA, Thibault GP, Stack RS, Coel MN, Furusato B, Sesterhenn IA.

Mol Imaging. 2008 Jan-Feb;7(1):12-20.

PMID:
18384719
35.

Quantitative analysis of a panel of gene expression in prostate cancer--with emphasis on NPY expression analysis.

Liu AJ, Furusato B, Ravindranath L, Chen YM, Srikantan V, McLeod DG, Petrovics G, Srivastava S.

J Zhejiang Univ Sci B. 2007 Dec;8(12):853-9. doi: 10.1631/jzus.2007.B0853.

36.

Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival.

Sterbis JR, Gao C, Furusato B, Chen Y, Shaheduzzaman S, Ravindranath L, Osborn DJ, Rosner IL, Dobi A, McLeod DG, Sesterhenn IA, Srivastava S, Cullen J, Petrovics G.

Clin Cancer Res. 2008 Feb 1;14(3):758-63. doi: 10.1158/1078-0432.CCR-07-1356.

37.

Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.

Rosner IL, Ravindranath L, Furusato B, Chen Y, Gao C, Cullen J, Sesterhenn IA, McLeod DG, Srivastava S, Petrovics G.

Urology. 2007 Dec;70(6):1225-9.

PMID:
18158066
38.

Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer.

Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA.

Mod Pathol. 2008 Feb;21(2):67-75. Epub 2007 Dec 7.

39.

Telomerase-immortalized non-malignant human prostate epithelial cells retain the properties of multipotent stem cells.

Li H, Zhou J, Miki J, Furusato B, Gu Y, Srivastava S, McLeod DG, Vogel JC, Rhim JS.

Exp Cell Res. 2008 Jan 1;314(1):92-102. Epub 2007 Aug 23.

PMID:
17900565
40.

Transcriptome analyses of benign and malignant prostate epithelial cells in formalin-fixed paraffin-embedded whole-mounted radical prostatectomy specimens.

Furusato B, Shaheduzzaman S, Petrovics G, Dobi A, Seifert M, Ravindranath L, Nau ME, Werner T, Vahey M, McLeod DG, Srivastava S, Sesterhenn IA.

Prostate Cancer Prostatic Dis. 2008;11(2):194-7. Epub 2007 Sep 4.

PMID:
17768422
41.

Silencing of Lactotransferrin expression by methylation in prostate cancer progression.

Shaheduzzaman S, Vishwanath A, Furusato B, Cullen J, Chen Y, Bañez L, Nau M, Ravindranath L, Kim KH, Mohammed A, Chen Y, Ehrich M, Srikantan V, Sesterhenn IA, McLeod D, Vahey M, Petrovics G, Dobi A, Srivastava S.

Cancer Biol Ther. 2007 Jul;6(7):1088-95.

PMID:
17568188
42.

Identification of putative stem cell markers, CD133 and CXCR4, in hTERT-immortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens.

Miki J, Furusato B, Li H, Gu Y, Takahashi H, Egawa S, Sesterhenn IA, McLeod DG, Srivastava S, Rhim JS.

Cancer Res. 2007 Apr 1;67(7):3153-61.

43.

Sarcoidosis of the prostate.

Furusato B, Koff S, McLeod DG, Sesterhenn IA.

J Clin Pathol. 2007 Mar;60(3):325-6. Review.

44.

Allelotyping analysis at chromosome arm 8p of high-grade prostatic intraepithelial neoplasia and incidental, latent, and clinical prostate cancers.

Lu W, Takahashi H, Furusato B, Maekawa S, Ikegami M, Sudo A, Egawa S, Hano H.

Genes Chromosomes Cancer. 2006 May;45(5):509-15.

PMID:
16470536
45.

Phenotypic characterization of telomerase-immortalized primary non-malignant and malignant tumor-derived human prostate epithelial cell lines.

Gu Y, Li H, Miki J, Kim KH, Furusato B, Sesterhenn IA, Chu WS, McLeod DG, Srivastava S, Ewing CM, Isaacs WB, Rhim JS.

Exp Cell Res. 2006 Apr 1;312(6):831-43. Epub 2006 Jan 17.

PMID:
16413016
46.

Quantitative expression profile of PSGR in prostate cancer.

Xu LL, Sun C, Petrovics G, Makarem M, Furusato B, Zhang W, Sesterhenn IA, McLeod DG, Sun L, Moul JW, Srivastava S.

Prostate Cancer Prostatic Dis. 2006;9(1):56-61.

PMID:
16231015
47.

Proteomic analysis of formalin-fixed prostate cancer tissue.

Hood BL, Darfler MM, Guiel TG, Furusato B, Lucas DA, Ringeisen BR, Sesterhenn IA, Conrads TP, Veenstra TD, Krizman DB.

Mol Cell Proteomics. 2005 Nov;4(11):1741-53. Epub 2005 Aug 9.

48.

Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome.

Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, Nau M, Ravindranath L, Chen Y, Dobi A, Srikantan V, Sesterhenn IA, McLeod DG, Vahey M, Moul JW, Srivastava S.

Oncogene. 2005 May 26;24(23):3847-52. Erratum in: Oncogene. 2007 Oct 11;26(46):6684. Furasato, Bungo [corrected to Furusato, Bungo].

PMID:
15750627
49.

Ultrasound-accelerated formalin fixation of tissue improves morphology, antigen and mRNA preservation.

Chu WS, Furusato B, Wong K, Sesterhenn IA, Mostofi FK, Wei MQ, Zhu Z, Abbondanzo SL, Liang Q.

Mod Pathol. 2005 Jun;18(6):850-63.

Supplemental Content

Loading ...
Support Center